The White House Just Opened the Door to Psychedelic Medicine
On April 18, Trump signed an EO fast-tracking federal review of psychedelic drugs — with ibogaine front and center. Joe Rogan was literally in the Oval Office.
Here’s what the order means:
→ $50M in federal research funding committed
→ FDA to fast-track psilocybin & ibogaine review
→ Right to Try pathway opened for desperately ill patients
→ DEA restrictions on clinical trials being reduced
→ 3 psychedelics added to FDA National Priority Voucher program
$PBM (Psyence Biomedical) was the top gainer — up 200%+ — as a clinical-stage ibogaine & psilocybin company with GMP manufacturing infrastructure already in place.
But the trade doesn’t stop there. Here’s the full watchlist 👇
Watchlist — Tiered by Relevance:
🥇 Most Direct Ibogaine Exposure
$PBM — GMP ibogaine manufacturer, Phase IIb psilocybin trials, small float (already moved hard)
$ATAI — owns DemeRx (Phase 1 ibogaine data), Peter Thiel backed, largest pure-play psychedelic biotech. Most direct public ibogaine play in the market. 
🥈 Psilocybin / Broader Psychedelic Plays (sentiment lift)
$CMPS (Compass Pathways) — Phase 3 trials for COMP360 in treatment-resistant depression, positive results already reported from first study 
$HELP (Cybin) — Phase 3 trials for CYB003, UK approval for second pivotal depression study, $500M financing secured 
$MNMD (MindMed) — LSD & ibogaine derivatives pipeline, pivotal Phase 3 data expected in 2026 
$GHRS (GH Research) — fast-acting inhaled psychedelic compound, shares more than doubled YTD 
The real catalyst is VA or DoD funding announcements — not the EO itself. The EO just funds the work to study it. Ibogaine also carries cardiac safety risks (QT prolongation) that make the clinical path harder than psilocybin. 
These are high-risk, pre-revenue biotechs. Most are pre-profitability. Position size accordingly.
Not financial advice. DYOR.
